Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo
Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval
In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24
Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.